Stryker Co. (NYSE:SYK) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI lessened its holdings in Stryker Co. (NYSE:SYK) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 69,859 shares of the medical technology company’s stock after selling 105 shares during the quarter. Stryker accounts for approximately 4.0% of Arcadia Investment Management Corp MI’s holdings, making the stock its 6th largest holding. Arcadia Investment Management Corp MI’s holdings in Stryker were worth $25,153,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter worth about $30,000. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the third quarter worth about $36,000. Activest Wealth Management purchased a new position in shares of Stryker in the fourth quarter worth about $36,000. Finally, Crews Bank & Trust purchased a new position in shares of Stryker in the fourth quarter worth about $39,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SYK shares. Robert W. Baird raised their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Stock Down 0.5 %

Stryker stock opened at $386.47 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business has a 50 day simple moving average of $377.92 and a 200-day simple moving average of $368.21. The stock has a market capitalization of $147.47 billion, a PE ratio of 49.80, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 EPS. On average, analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.